Review of atazanavir: a novel HIV protease inhibitor.
Atazanavir is a novel and potent protease inhibitor that differs from other protease inhibitors because of its good gastrointestinal tolerability, once-daily dosing, low pill burden and it does not seem to cause insulin resistance or lipid elevations in short-term use. Atazanavir produces an increase in indirect bilirubin levels, which is not related to hepatotoxicity. The incidence of atazanavir-related hyperbilirubinaemia does not seem to be increased in hepatitis B or C coinfection. I50L is atazanavir's signature mutation. It has been shown in previously treated patients that resistance is likely when three or more protease inhibitor resistance-related primary mutations are present.
Fuster
Daniel
D
HIV Clinical Unit/Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
Clotet
Bonaventura
B
D000284:Administration, Oral; D000818:Animals; D000069446:Atazanavir Sulfate; D000075202:Contraindications; D017277:Drug Approval; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D006678:HIV / Q000187:drug effects* / Q000201:enzymology; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010349:Patient Compliance; D011725:Pyridines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000008:administration & dosage
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019438:Ritonavir